Research programme: microRNA-targeted therapeutics - Rosetta Genomics

Drug Profile

Research programme: microRNA-targeted therapeutics - Rosetta Genomics

Alternative Names: miR-34a therapeutics - Rosetta/Weizmann Institute

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rosetta Genomics
  • Developer Rosetta Genomics; Weizmann Institute of Science
  • Class Antisense oligonucleotides
  • Mechanism of Action RNA inhibitors; Tumour suppressor protein p53 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral)
  • 06 Feb 2017 Rosetta Genomics receives patent allowance for hsa-miR-146-5p and hsa-miR-551b-3p for the treatment of Cancer in USA
  • 23 Sep 2015 Rosetta Genomics receives patent allowance for anti-hsa-miR-210 for the treatment of Prostate cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top